{"id":"methenamine","rwe":[{"pmid":"41875198","year":"2026","title":"Implications for methenamine hippurate use in recurrent urinary tract infection management: Formaldehyde resistance and altered urinary composition.","finding":"","journal":"PLoS pathogens","studyType":"Clinical Study"},{"pmid":"41868390","year":"2026","title":"Diagnostic odyssey of a German shepherd dog with disseminated Penicillium labradoris infection: a case report.","finding":"","journal":"Frontiers in veterinary science","studyType":"Clinical Study"},{"pmid":"41865398","year":"2026","title":"Nocardiosis: clinical and pathologic examination of 140 cases representing 18 species in 6 complexes.","finding":"","journal":"American journal of clinical pathology","studyType":"Clinical Study"},{"pmid":"41843964","year":"2026","title":"Rhinofacial pythiosis with basilar empyema in a lamb.","finding":"","journal":"Journal of comparative pathology","studyType":"Clinical Study"},{"pmid":"41811789","year":"2025","title":"Primary Care Provider Practice Patterns in the Management of Recurrent UTI.","finding":"","journal":"Urogynecology (Philadelphia, Pa.)","studyType":"Clinical Study"}],"_fda":{"id":"498de24d-a25d-44b9-a75d-596d77919f0c","set_id":"02af5576-d75c-4553-9431-9c482997c8bb","openfda":{"upc":["0036800444744"],"unii":["J50OIX95QV","WIQ1H85SYP"],"route":["ORAL"],"rxcui":["1489932"],"spl_id":["498de24d-a25d-44b9-a75d-596d77919f0c"],"brand_name":["TopCare Antibacterial Plus Urinary Pain Relief"],"spl_set_id":["02af5576-d75c-4553-9431-9c482997c8bb"],"package_ndc":["36800-314-24"],"product_ndc":["36800-314"],"generic_name":["METHENAMINE, SODIUM SALICYLATE"],"product_type":["HUMAN OTC DRUG"],"substance_name":["METHENAMINE","SODIUM SALICYLATE"],"manufacturer_name":["Topco Associates LLC"],"is_original_packager":[true]},"purpose":["Purpose Antibacterial Analgesic (pain reliever)"],"version":"3","warnings":["Warnings Reye's syndrome: Children and teenagers who have or are recovering from chicken pox or flu-like symptoms should not use this product. If changes in behaviour with nausea and vomiting occur, consult a doctor because these symptoms could be an early sign of Reye's syndrome, a rare but serious illness. Stomach bleeding warning: This product contains an NSAID, which may cause stomach bleeding. The chance is higher if you: • take other drugs containing prescription or nonprescription NSAIDs (aspirin, ibuprofen, naproxen or others) • have 3 or more alcoholic drinks every day while using this product • have stomach ulcers or bleeding problems • take a blood thinning (anticoagulant) or steroid drug • are age 60 or older • take more or for a longer time than directed Do not use: • if you are on a sodium restricted diet • if you are allergic to salicylates (including aspirin) unless directed by a doctor • if you have stomach problems (such as heartburn, upset stomach, or stomach pain) that persist or recur, or if you have ulcers or bleeding problems unless directed by a doctor Ask a doctor before use if you have • frequent, burning urination for the first time • the stomach bleeding warning applying to you • history of stomach problems, such as heartburn • high blood pressure • heart disease • liver cirrhosis • bleeding problems • diuretic use • ulcers • kidney disease • reached age 60 or older Ask a doctor or pharmacist before use if you are • taking any other drug containing an NSAID (prescription or nonprescription) • taking a blood thinning (anticoagulant), steroid, diabetes, gout or arthritis drug When using this product • do not take more than the recommended dosage Stop and ask a doctor if • product has been used for 3 days • you experience any of the following signs of stomach bleeding: • feel faint, vomit blood • have bloody or black stools • have stomach pain that does not get better • ringing in the ears or a loss of hearing occurs If pregnant or breast feeding, ask a health professional before use."],"effective_time":"20241218","active_ingredient":["Active Ingredients (in each tablet): Methenamine 162 mg Sodium Salicylate 162.5 mg (NSAID Nonsteroidal Anti-Inflammatory Drug)"],"inactive_ingredient":["Inactive ingredients: benzoic acid, croscarmellose sodium, fd&c red #40, fd&c yellow #6, hypromellose, magnesium stearate, methacrylic acid-ethyl acrylate copolymer, microcrystalline cellulose, silicon dioxide, stearic acid, sodium bicarbonate, sodium lauryl sulfate, talc, titanium dioxide, triacetin, triethyl citrate"],"storage_and_handling":["Other Information: • each tablet contains 25 mg of sodium • store at 59-86°F (15-30°C) in a dry place • protect from light • Tamper evident: tablets sealed in blisters. Do not use if blister foil or seal is open or damaged."],"indications_and_usage":["Uses Temporarily relieves: pain & burning • frequency and urgency of urination"],"spl_unclassified_section":["Drug Facts","HELPS CONTROL THE INFECTION* PLUS GENERAL PAIN RELIEVER Antibacterial Urinary Pain Relief Methenamine and Sodium Salicylate (NSAID)"],"dosage_and_administration":["Directions: Adults and children 12 years and over: take 2 tablets with a full glass of water 3 times a day. Drink plenty of fluids. Children under 12 years: ask a doctor"],"spl_product_data_elements":["TopCare Antibacterial Plus Urinary Pain Relief METHENAMINE, SODIUM SALICYLATE METHENAMINE METHENAMINE SODIUM SALICYLATE SALICYLIC ACID BENZOIC ACID CROSCARMELLOSE SODIUM FD&C RED NO. 40 FD&C YELLOW NO. 6 HYPROMELLOSES MAGNESIUM STEARATE METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A CELLULOSE, MICROCRYSTALLINE SILICON DIOXIDE STEARIC ACID SODIUM BICARBONATE SODIUM LAURYL SULFATE TALC TITANIUM DIOXIDE TRIACETIN TRIETHYL CITRATE PH061"],"keep_out_of_reach_of_children":["Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away."],"package_label_principal_display_panel":["Packaging carton"]},"tags":[{"label":"methenamine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"J01XX05","category":"atc"},{"label":"Extracorporeal","category":"route"},{"label":"Oral","category":"route"},{"label":"Capsule","category":"form"},{"label":"Liquid","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Prevention of Bacterial Urinary Tract Infection","category":"indication"},{"label":"Urinary tract infectious disease","category":"indication"},{"label":"Esjay Pharma","category":"company"},{"label":"Approved 1960s","category":"decade"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Anti-Infective Agents, Urinary","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":128.57,"date":"","count":101,"signal":"Urinary tract infection","source":"DrugCentral FAERS","actionTaken":"Reported 101 times (LLR=129)"},{"llr":26.463,"date":"","count":5,"signal":"Thyroid cancer metastatic","source":"DrugCentral FAERS","actionTaken":"Reported 5 times (LLR=26)"},{"llr":23.342,"date":"","count":14,"signal":"Multiple sclerosis","source":"DrugCentral FAERS","actionTaken":"Reported 14 times (LLR=23)"},{"llr":23.319,"date":"","count":6,"signal":"Drug monitoring procedure not performed","source":"DrugCentral FAERS","actionTaken":"Reported 6 times (LLR=23)"},{"llr":21.407,"date":"","count":6,"signal":"Secondary progressive multiple sclerosis","source":"DrugCentral FAERS","actionTaken":"Reported 6 times (LLR=21)"},{"llr":20.038,"date":"","count":8,"signal":"Urine analysis abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 8 times (LLR=20)"},{"llr":19.939,"date":"","count":92,"signal":"Fatigue","source":"DrugCentral FAERS","actionTaken":"Reported 92 times (LLR=20)"},{"llr":19.677,"date":"","count":11,"signal":"Pathogen resistance","source":"DrugCentral FAERS","actionTaken":"Reported 11 times (LLR=20)"},{"llr":19.282,"date":"","count":17,"signal":"Cystitis","source":"DrugCentral FAERS","actionTaken":"Reported 17 times (LLR=19)"},{"llr":19.08,"date":"","count":7,"signal":"Osteitis","source":"DrugCentral FAERS","actionTaken":"Reported 7 times (LLR=19)"}],"commonSideEffects":[{"effect":"Nausea","drugRate":"3.5%","severity":"common","organSystem":""},{"effect":"Upset stomach","drugRate":"3.5%","severity":"common","organSystem":""},{"effect":"Dysuria","drugRate":"3.5%","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"3.5%","severity":"common","organSystem":""}],"contraindications":["Achalasia of esophagus","Acute hepatitis","Acute nephropathy","Anemia","Anemia due to enzyme deficiency","Atony of colon","Benign prostatic hyperplasia","Bladder outflow obstruction","Blood coagulation disorder","Body fluid retention","Breastfeeding (mother)","Cardiovascular event risk","Chronic heart failure","Cirrhosis of liver","Conduction disorder of the heart","Deficiency of glucose-6-phosphate dehydrogenase","Diabetes mellitus","Disease of liver","Disorder of autonomic nervous system","Disorder of cardiovascular system","Disorder of coronary artery","Edema","Factor II deficiency","Fever greater than 100.4 Fahrenheit","Gastritis"],"specialPopulations":{"Pregnancy":"Teratogenic effects. Pregnancy category C. Oral administration of methenamine to pregnant dogs, at doses equivalent to the human dose, has been reported to cause slight increase in the stillborn rate and slight impairment of weight gain and survival of live-born offspring. teratogenicity study, in which methenamine hippurate was administered to pregnant rabbits at doses approximately times human dose, revealed no evidence of harm to the fetus. There are no adequate and well-controlled","Geriatric use":"Clinical studies of methenamine hippurate tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal","Paediatric use":"see DOSAGE AND ADMINISTRATION","Hepatic impairment":"decreased hepatic"},"seriousAdverseEvents":[]},"trials":[],"aliases":[],"company":"Esjay Pharma","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=METHENAMINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:11:07.942931+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:11:14.415385+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=METHENAMINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:11:14.778207+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:11:06.843370+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:11:06.843397+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201270/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:11:15.473832+00:00"}},"allNames":"hiprex","offLabel":[],"synonyms":["hexamethylenetetramine","methenamine","hexamethylenamine","hexamine","methenamin","methenamine hippurate","hexamethylenetetramine hippurate","hexamethylenetetramine hippuric acid complex","methenamine mandelate"],"timeline":[{"date":"1967-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from CNTY LINE PHARMS to Esjay Pharma"},{"date":"1967-07-05","type":"positive","source":"DrugCentral","milestone":"FDA approval (Cnty Line Pharms)"},{"date":"2019-08-01","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 3 manufacturers approved"}],"aiSummary":"Hiprex (METHENAMINE) is a small molecule drug developed by CNTY LINE PHARMS and currently owned by Esjay Pharma. It is used to prevent and treat bacterial urinary tract infections. Hiprex is an off-patent medication with multiple generic manufacturers. It was first approved by the FDA in 1967 for the prevention of bacterial urinary tract infections and urinary tract infectious diseases. As an off-patent medication, Hiprex is widely available in the market.","approvals":[{"date":"1967-07-05","orphan":false,"company":"CNTY LINE PHARMS","regulator":"FDA"}],"brandName":"Hiprex","ecosystem":[{"indication":"Prevention of Bacterial Urinary Tract Infection","otherDrugs":[],"globalPrevalence":null},{"indication":"Urinary tract infectious disease","otherDrugs":[{"name":"Polymyxin B","slug":"polymyxin-b","company":"Monarch Pharms"},{"name":"acetohydroxamic acid","slug":"acetohydroxamic-acid","company":"Mission Pharma"},{"name":"alatrofloxacin","slug":"alatrofloxacin","company":"Pfizer"},{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"}],"globalPrevalence":null}],"mechanism":{"novelty":"Follow-on","modality":"Small Molecule","drugClass":"methenamine","explanation":"","oneSentence":"","technicalDetail":"Methenamine is a weak acid that is converted to formaldehyde in an acidic environment, such as the urine. Formaldehyde then acts as a bacteriostatic agent, inhibiting the growth of bacteria and preventing the development of urinary tract infections."},"commercial":{"launchDate":"1967","_launchSource":"DrugCentral (FDA 1967-07-05, CNTY LINE PHARMS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3344","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=METHENAMINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=METHENAMINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T12:38:02.766293","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:11:17.450781+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"fosfomycin","drugSlug":"fosfomycin","fdaApproval":"1996-12-19","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"spectinomycin","drugSlug":"spectinomycin","fdaApproval":"1971-06-30","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"linezolid","drugSlug":"linezolid","fdaApproval":"2000-04-18","genericCount":24,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"daptomycin","drugSlug":"daptomycin","fdaApproval":"2003-09-12","patentExpiry":"Sep 4, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"bacitracin","drugSlug":"bacitracin","fdaApproval":"1948-07-29","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tedizolid phosphate","drugSlug":"tedizolid-phosphate","fdaApproval":"2014-06-20","patentExpiry":"Jun 20, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"lefamulin","drugSlug":"lefamulin","fdaApproval":"2019-08-19","patentExpiry":"May 23, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"methenamine","indications":{"approved":[{"name":"Prevention of Bacterial Urinary Tract Infection","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults and children with frequently recurring urinary tract infections, after eradication of the infection by other appropriate antimicrobial agents"},{"name":"Urinary tract infectious disease","source":"DrugCentral","snomedId":68566005,"regulator":"FDA","eligibility":"Not explicitly stated, but implied to be adults and children with urinary tract infections proven or strongly suspected to be caused by susceptible bacteria"}],"offLabel":[],"pipeline":[]},"currentOwner":"Esjay Pharma","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"fosfomycin","brandName":"fosfomycin","genericName":"fosfomycin","approvalYear":"1996","relationship":"same-class"},{"drugId":"spectinomycin","brandName":"spectinomycin","genericName":"spectinomycin","approvalYear":"1971","relationship":"same-class"},{"drugId":"linezolid","brandName":"linezolid","genericName":"linezolid","approvalYear":"2000","relationship":"same-class"},{"drugId":"daptomycin","brandName":"daptomycin","genericName":"daptomycin","approvalYear":"2003","relationship":"same-class"},{"drugId":"bacitracin","brandName":"bacitracin","genericName":"bacitracin","approvalYear":"1948","relationship":"same-class"},{"drugId":"tedizolid-phosphate","brandName":"tedizolid phosphate","genericName":"tedizolid phosphate","approvalYear":"2014","relationship":"same-class"},{"drugId":"lefamulin","brandName":"lefamulin","genericName":"lefamulin","approvalYear":"2019","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04709601","phase":"PHASE4","title":"Efficacy and Mechanism of Action of Methenamine Hippurate (Hiprex™) in Women With Recurring Urinary Tract Infections.","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2021-01-04","conditions":["Urinary Tract Infections"],"enrollment":14,"completionDate":"2024-12-31"},{"nctId":"NCT07202949","phase":"PHASE2","title":"A Clinical Trial of Extended (High) Treatment Dose Antibiotics in Combination With Methenamine Hippurate Compared to the Standard of Care (Either Prophylactic (Low) Dose Antibiotic Treatment or Methenamine Hippurate) in Females With Chronic Urinary Tract Infection","status":"NOT_YET_RECRUITING","sponsor":"University College, London","startDate":"2026-02-28","conditions":["Chronic Urinary Tract Infection"],"enrollment":192,"completionDate":"2027-11"},{"nctId":"NCT06710899","phase":"EARLY_PHASE1","title":"Vitamin C and Hiprex in rUTI","status":"NOT_YET_RECRUITING","sponsor":"University Hospitals of North Midlands NHS Trust","startDate":"2027-01","conditions":["Urinary Tract Infections"],"enrollment":20,"completionDate":"2028-01"},{"nctId":"NCT06953271","phase":"PHASE4","title":"Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection","status":"NOT_YET_RECRUITING","sponsor":"Women and Infants Hospital of Rhode Island","startDate":"2025-05-15","conditions":["Overactive Bladder (OAB)","Urinary Tract Infection (Diagnosis)"],"enrollment":164,"completionDate":"2027-01-01"},{"nctId":"NCT05658874","phase":"PHASE3","title":"A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jocelyn Fitzgerald","startDate":"2022-12-01","conditions":["Interstitial Cystitis"],"enrollment":26,"completionDate":"2025-10-31"},{"nctId":"NCT06810687","phase":"NA","title":"Is Methenamine Prophylaxis for Urinary Tract Infection After Midurethral Sling as Effective as Antibiotic Prophylaxis?","status":"RECRUITING","sponsor":"Atlantic Health System","startDate":"2025-01-30","conditions":["Urinary Tract Infection (Diagnosis)"],"enrollment":190,"completionDate":"2028-01-30"},{"nctId":"NCT04077580","phase":"PHASE4","title":"The Effect of Methenamine Hippurate to Reduce Antibiotic Prescribing in Elderly Women With Recurrent UTI","status":"COMPLETED","sponsor":"University of Oslo","startDate":"2019-11-01","conditions":["Recurrent Urinary Tract Infection"],"enrollment":289,"completionDate":"2023-06-30"},{"nctId":"NCT03407157","phase":"PHASE3","title":"Oral Probiotic Supplementation in Pregnancy to Reduce Group B Streptococcus Colonization","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2020-01-16","conditions":["Group B Streptococcus Carrier in Childbirth"],"enrollment":168,"completionDate":"2024-12-31"},{"nctId":"NCT03586531","phase":"","title":"Renal Biopsy Unexplained Elevated Serum Creatinine","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-06-13","conditions":["Renal Impairment"],"enrollment":210,"completionDate":"2022-05-01"},{"nctId":"NCT03818321","phase":"PHASE2","title":"Urinary Track Infection Prevention After Urogynecological Surgery","status":"COMPLETED","sponsor":"TriHealth Inc.","startDate":"2019-06-17","conditions":["Urinary Tract Infections","Urinary Retention Postoperative","Pelvic Organ Prolapse"],"enrollment":185,"completionDate":"2021-07-01"},{"nctId":"NCT02637986","phase":"NA","title":"The Efficacy of Orally Administrated Probiotic Formula in Preventing a Recurrence of a Urinary Tract Infection During Pregnancy","status":"WITHDRAWN","sponsor":"HaEmek Medical Center, Israel","startDate":"2022-11-07","conditions":["Urinary Tract Infections (UTIs)"],"enrollment":0,"completionDate":"2022-11-07"},{"nctId":"NCT03996057","phase":"PHASE4","title":"Methenamine in a Non-antibiotic, Multimodal Approach to UTI Prevention","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2018-06-20","conditions":["UTI","Female Urogenital Diseases","UTI - Lower Urinary Tract Infection"],"enrollment":0,"completionDate":"2022-02-11"},{"nctId":"NCT02358993","phase":"NA","title":"Short-course Methenamine Hippurate for Prevention of Post-operative UTI","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2014-12","conditions":["Urinary Tract Infections","Catheter-Related Infections"],"enrollment":201,"completionDate":"2020-09-30"},{"nctId":"NCT03379389","phase":"PHASE4","title":"Clinical Assessment of Urinary Antiseptics Methenamine and Methylthioninium in Recurrent Cystitis","status":"COMPLETED","sponsor":"Fundação Educacional Serra dos Órgãos","startDate":"2018-03-31","conditions":["Urinary Tract Infections"],"enrollment":284,"completionDate":"2021-06-01"},{"nctId":"NCT05082363","phase":"","title":"The Expression Profile of New Complement Components in Childhood Lupus Nephritis","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-11","conditions":["Lupus Nephritis"],"enrollment":30,"completionDate":"2022-08"},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":["Osteomyelitis"],"enrollment":11,"completionDate":"2018-11-07"},{"nctId":"NCT01657448","phase":"PHASE3","title":"Efficacy Study of Methenamine + Methylthioninium Chloride vs Phenazopyridine for the Symptomatic Control of Dysuria","status":"COMPLETED","sponsor":"EMS","startDate":"2016-06-27","conditions":["Dysuria"],"enrollment":316,"completionDate":"2017-12-22"},{"nctId":"NCT03077711","phase":"PHASE4","title":"Methenamine Hippurate Versus Trimethoprim in the Prevention of Recurrent UTIs","status":"COMPLETED","sponsor":"Endeavor Health","startDate":"2016-06","conditions":["Urinary Tract Infections, Recurrent"],"enrollment":92,"completionDate":"2019-06-21"},{"nctId":"NCT02430246","phase":"NA","title":"The Association Between the Transfer of Lactobacilli From the Gastrointestinal Tract to the Vagina and the Prevention / Eradication of Abnormal Vaginal Flora in High Risk Pregnancies","status":"TERMINATED","sponsor":"HaEmek Medical Center, Israel","startDate":"2016-01","conditions":["Pregnancy"],"enrollment":40,"completionDate":"2019-01-10"},{"nctId":"NCT00664820","phase":"NA","title":"Effects of Probiotics on Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2008-03","conditions":["Rheumatoid Arthritis"],"enrollment":50,"completionDate":"2009-07"},{"nctId":"NCT00767988","phase":"PHASE2","title":"Probiotics in Girls With Spina Bifida","status":"WITHDRAWN","sponsor":"Baylor College of Medicine","startDate":"","conditions":["Urinary Tract Infection"],"enrollment":0,"completionDate":""},{"nctId":"NCT00781625","phase":"NA","title":"Probiotics as a Prophylactic Aid in Women With Recurrent Urinary Tract Infections (UTI's)","status":"UNKNOWN","sponsor":"University Hospital, Akershus","startDate":"2008-10","conditions":["Urinary Tract Infections"],"enrollment":120,"completionDate":"2010-12"},{"nctId":"NCT00717600","phase":"PHASE1","title":"Bacteriuria Eradication Through Probiotics","status":"UNKNOWN","sponsor":"Baylor College of Medicine","startDate":"2008-01","conditions":["Bacteriuria"],"enrollment":10,"completionDate":"2008-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Capsule, Liquid","formulations":[{"form":"CAPSULE","route":"ORAL","productName":"Vilamit MB"},{"form":"CAPSULE","route":"ORAL","productName":"URO-SP"},{"form":"CAPSULE","route":"ORAL","productName":"URIBEL"},{"form":"CAPSULE","route":"ORAL","productName":"URIMAR-T CAPS"},{"form":"CAPSULE","route":"ORAL","productName":"UrNeva"},{"form":"CAPSULE","route":"ORAL","productName":"Uro-MP"},{"form":"CAPSULE","route":"ORAL","productName":"UroAv-B"},{"form":"CAPSULE","route":"ORAL","productName":"Ustell"},{"form":"LIQUID","route":"EXTRACORPOREAL","productName":"Air Disinfectant"},{"form":"LIQUID","route":"EXTRACORPOREAL","productName":"Cleaning Disinfectant"},{"form":"LIQUID","route":"EXTRACORPOREAL","productName":"Disinfectant(Model III)Sanitizer Hand And Surface"},{"form":"LIQUID","route":"EXTRACORPOREAL","productName":"Youjie Weishi  Rinse-free Hand Disinfectant"},{"form":"LIQUID","route":"EXTRACORPOREAL","productName":"Youjie Weishi Air Disinfectant"},{"form":"LIQUID","route":"EXTRACORPOREAL","productName":"Youjie Weishi Cloth Cleaning Disinfectant"},{"form":"LIQUID","route":"EXTRACORPOREAL","productName":"Youjie Weishi Disinfectant"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146894","MMSL":"5069","NDDF":"002861","UNII":"J50OIX95QV","VUID":"4018578","CHEBI":"CHEBI:6824","VANDF":"4017868","INN_ID":"119","RXNORM":"161623","UMLSCUI":"C0025638","chemblId":"CHEMBL1201270","ChEMBL_ID":"CHEMBL1201270","KEGG_DRUG":"D00393","DRUGBANK_ID":"DB06799","PUBCHEM_CID":"4101","SNOMEDCT_US":"372773008","IUPHAR_LIGAND_ID":"10913","SECONDARY_CAS_RN":"5714-73-8","MESH_DESCRIPTOR_UI":"D008709","MESH_SUPPLEMENTAL_RECORD_UI":"C011481"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1967-","companyName":"Cnty Line Pharms","relationship":"Original Developer"},{"period":"present","companyName":"Esjay Pharma","relationship":"Current Owner"}],"publicationCount":1657,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"J01XX05","allCodes":["J01XX05"]},"biosimilarFilings":[],"originalDeveloper":"Cnty Line Pharms","recentPublications":[{"date":"2026 Mar","pmid":"41875198","title":"Implications for methenamine hippurate use in recurrent urinary tract infection management: Formaldehyde resistance and altered urinary composition.","journal":"PLoS pathogens"},{"date":"2026","pmid":"41868390","title":"Diagnostic odyssey of a German shepherd dog with disseminated Penicillium labradoris infection: a case report.","journal":"Frontiers in veterinary science"},{"date":"2026 Mar 3","pmid":"41865398","title":"Nocardiosis: clinical and pathologic examination of 140 cases representing 18 species in 6 complexes.","journal":"American journal of clinical pathology"},{"date":"2026 Mar 16","pmid":"41843964","title":"Rhinofacial pythiosis with basilar empyema in a lamb.","journal":"Journal of comparative pathology"},{"date":"2025 Oct 6","pmid":"41811789","title":"Primary Care Provider Practice Patterns in the Management of Recurrent UTI.","journal":"Urogynecology (Philadelphia, Pa.)"}],"companionDiagnostics":[],"genericManufacturers":6,"_genericFilersChecked":true,"genericManufacturerList":["Aurobindo Pharma Ltd","Impax Labs Inc","Ingenus Pharms Llc","Jubilant Cadista","Micro Labs","Zydus Lifesciences"],"status":"approved","companyName":"Esjay Pharma","companyId":"esjay-pharma","modality":"Small molecule","firstApprovalDate":"1967","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1967-07-05T00:00:00.000Z","mah":"CNTY LINE PHARMS","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:11:17.450781+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}